The 43rd ASCO annual meeting and exposition will be held at the McCormick Place on June 1-5, 2007, Chicago, IL. The ASCO Annual Meeting is considered the premier educational and scientific event in the oncology community. The 2006 Meeting in Atlanta attracted more than 29,000 attendees from all over the world.
The American Society of Clinical Oncology (ASCO) is a non-profit organization, founded in 1964, with overarching goals of improving cancer care and prevention and ensuring that all patients with cancer receive care of the highest quality. Nearly 25,000 oncology practitioners belong to ASCO, representing all oncology disciplines (medical, radiologic, and surgical oncology) and subspecialties. Members include physicians and health-care professionals participating in approved oncology training programs, oncology nurses, and other practitioners with a predominant interest in oncology.

The Bing Center for Waldenstrom’s Macroglobulinemia was honored and presents two oral sessions on “Long-term responses to thalidomide and rituximab in Waldenstrom's macroglobulinemia” Jacob Soumerai and “Increased incidence of disease transformation and development of MDS/AML in Waldenstrom’s Macroglobulinemia (WM) patients treated with nucleoside analogues” Xavier Leleu.

The poster discussion is “IgG and IgA hypogammaglobulinemia is pervasive in Waldenstrom's macroglobulinemia (WM) and persists regardless of response or type of therapeutic intervention.” By Zachary Hunter.

The oral presenter’s of the Bing Center for WM will be Dr. Xavier Leleu and Jacob Soumerai. The poster discussion will be presented and discussed by Zachary Hunter.
If you have any questions regarding their work, please contact them via email.